多尔佐胺/蒂莫洛尔/布里莫尼丁的三重固定组合:在玻利维亚人口中的有效性研究
Manuel José Justiniano1, Giselle Marisa Rodríguez2, Maria Silvia Passerini2
1Clínica de Ojos Norte, Santa Cruz de la Sierra, Bolivia.
Journal of current glaucoma practice
|March 20, 2025
概括
切换到多尔佐胺/蒂莫洛尔/布里莫尼丁固定组合 (DTB-FC) 眼药,有效降低了中期青光瘤患者的眼内压力 (IOP). 这种三重组合疗法可以改善初级开角 (POAG) 和慢性闭角玻璃眼 (CACG) 的治疗.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 眼管理需要有效的眼内压力 (IOP) 降低.
- 中期青光瘤患者可能需要优化治疗策略.
研究的目的:
- 为了评估转换到2%的多尔佐胺/0.5%的蒂莫洛尔/0.2%的布里莫尼丁酸盐固定组合 (DTB-FC) 的疗效,在中级玻璃眼患者.
- 评估DTB-FC对初级开视角光眼 (POAG) 或慢性闭视角光眼 (CACG) 患者的眼内压力 (IOP) 的影响.
主要方法:
- 一个回顾性病例系列包括中期POAG或CACG的患者.
- 患者从多佐胺/蒂莫洛尔固定组合 (DT-FC) 转换为DTB-FC.
- 眼内压力 (IOP) 在基线和各种随访点被测量到1年. 差异分析 (ANOVA) 用于IOP比较.
主要成果:
- DTB-FC显著降低了从基线20.3 mm Hg的平均IOP,到1年后的15.3 mm Hg (p > 0.001).
- 一年后,IOP的平均降低为-5.0mm Hg.
- 在随访期间,治疗成功率在66.7%至86.1%之间,POAG和CACG之间没有显著差异.
结论:
- 切换到DTB-FC眼滴是有效的减少中级POAG或CACG患者的IOP.
- DTB-FC疗法改善了对玻璃眼的治疗,并可能有助于预防疾病的进展.
更多相关视频
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
186
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
663
相关概念视频
01:27Open Angle Glaucoma: Treatment
378
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
378
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
398
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
398
01:17Antihypertensive Drugs: Action of β1 Blockers
295
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
295
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
520
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
520
01:28Antihypertensive Drugs: Types of β-Blockers
543
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
543